Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05427370 · ClinicalTrials.gov registry record · NA
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
A NA study of Coronary Artery Disease and Heart Failure, Systolic, sponsored by Sunnybrook Health Sciences Centre.
- Recruiting
- Registry status
- NA
- Development phase
- 754
- Enrollment target
- 20
- Study locations
NCT05427370: Recruiting NA study of Coronary Artery Disease and Heart Failure, Systolic, sponsored by Sunnybrook Health Sciences Centre.
NCT05427370 is a NA study of Coronary Artery Disease and Heart Failure, Systolic that is actively recruiting participants, run by Sunnybrook Health Sciences Centre. The registered enrollment target is 754 participants, below the 1,284-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05427370, a NA study of Coronary Artery Disease and Heart Failure, Systolic, is actively recruiting participants, sponsored by Sunnybrook Health Sciences Centre.
- RECRUITING
- Registry status
- NA
- Development phase
- 754 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy (STICH3C) trial is a prospective, unblinded, international multi-center randomized trial of 754 subjects enrolled in approximately 45 centers comparing revascularization by percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with multivessel/left main (LM) coronary artery disease (CAD) and reduced left ventricular ejection fraction (LVEF). The primary objective is to determine whether CABG compared to PCI is associated with a reduction in all-cause death, stroke, spontaneous myocardial infarction (MI), urgent repeat revascularization (RR), or heart failure (HF) readmission over a median follow-up of 5 years in patients with multivessel/LM CAD and ischemic left ventricular dysfunction (iLVSD). Eligible patients are considered by the local Heart Team appropriate and amenable for non-emergent revascularization by both modes of revascularization. The secondary objectives are to describe the early risks of both procedures, and a comprehensive set of patient-reported outcomes longitudinally.
Primary Outcome
Time to event outcome measured as the time from randomization to the occurence of the first event.
Conditions Studied
Interventions
- PROCEDURE Revascularization by PCI
- PROCEDURE Revascularization by CABG
Study Locations (20)
Ontario
- Hamilton General Hospital - Hamilton
- London Health Sciences Center, University Hospital - London
- Southlake Regional HC - Newmarket
- Ottawa Heart Institute - Ottawa
- Sunnybrook Health Sciences Center - Toronto
- St. Michael's - Toronto
- Toronto General Hospital - Toronto
Other
- Medical University of Vienna - Vienna
- Heart Institute, Medical School of the University of Sao Paulo_INCOR - São Paulo
Alberta
- University of Calgary; Libin Cardiovascular Institute - Calgary
- Mackenzie Health Sciences Center - Edmonton
British Columbia
- Fraser Health; Royal Columbian Hospital - New Westminster
- Providence Health - Vancouver
California
- Cedars-Sinai - Los Angeles
Connecticut
- Yale University - New Haven
Kentucky
- UofL Health, Inc - Louisville
Maryland
- John Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 754 participants |
| Start Date | 2023-06-22 |
| Est. Completion | 2029-12 |
| Phase | NA |
What NCT05427370 shows while recruiting
NCT05427370 is an interventional study that assigns participants to a tested intervention. The registered 754 participants enrollment target is mid-sized for trials with a published cap, below the 1,284-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (41% lower).
The record links to 2 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Revascularization by PCI is the first listed.
NCT05427370 names 20 study sites across 11 states, led by Ontario, Other, Alberta.
Frequently Asked Questions
What is clinical trial NCT05427370 about?
NCT05427370 is a clinical study titled "The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)". The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy (STICH3C) trial is a prospective, unblinded, international multi-center randomized trial of 754 subjects enrolled in approximately 45 centers comparing revascularization by percutaneous coronary intervention (PCI) vs. coronary artery ...
What is the current status of trial NCT05427370?
This trial is currently recruiting. It is a NA study. The enrollment target is 754 participants. The study started on 2023-06-22. Estimated completion is 2029-12.
What conditions does trial NCT05427370 study?
This clinical trial studies the following conditions: Coronary Artery Disease, Heart Failure, Systolic.
What interventions are being tested in trial NCT05427370?
The interventions under investigation include: Revascularization by PCI (PROCEDURE), Revascularization by CABG (PROCEDURE).
Who is sponsoring clinical trial NCT05427370?
This trial is sponsored by Sunnybrook Health Sciences Centre, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05427370 being conducted?
This trial has 20 study locations across California, Connecticut, Kentucky, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05427370's enrollment target sits among peer trials
754 59th of 219 higher than 161 of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
RECRUITING · NA
-
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
RECRUITING · NA
-
Intravascular Lithotripsy With or Without Rotational Atherectomy for Coronary Calcified Nodule Treatment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05379985 · 754 participants · Phase 1
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- NCT05869149 · 756 participants · NA
Systems Science Approaches to Improve Access to Healthier Foods: The FRESH Trial
- NCT06095583 · 756 participants · Phase 3
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
- NCT06559306 · 752 participants · Phase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI